Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of Depo-Provera before intravaginal challenge with simian immunodeficiency virus mac239

Kristina Abel, Tracy Rourke, Ding Lu, Kristen Bost, Michael B. McChesney, Chris J Miller

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

In nonhuman primate models of acquired immunodeficiency syndrome, live attenuated lentiviruses provide the most reliable protection from systemic and mucosal challenge with pathogenic simian immunodeficiency virus (SIV). Although live attenuated lentiviruses may never be used in humans because of safety concerns, understanding the nature of the protective immune mechanisms induced by live attenuated vaccines in primate models will be useful for developing other vaccine approaches. Approximately 60% of rhesus macaques immunized with nonpathogenic simian-human immunodeficiency virus (SHIV) strain 89.6 are protected from infection or clinical disease after intravaginal (IVAG) challenge with pathogenic SIVmac239. The goal of the present study was to determine whether administration of Depo-Provera before IVAG challenge with SIV decreases the protective efficacy of infection with SHIV89.6. The rate of protection after IVAG challenge with SIVmac239 was significantly lower (P < .05), and the acute postchallenge plasma viral RNA levels were significantly higher (P < .006), in Depo-Provera-treated, SHIV89.6-immunized macaques than in Depo-Proveranaive, SHIV89.6-immunized macaques. In the primate model of sexual transmission of human immunodeficiency virus, treatment with progesterone before IVAG challenge with a pathogenic virus can decrease the efficacy of a model "vaccine.".

Original languageEnglish (US)
Pages (from-to)1697-1705
Number of pages9
JournalJournal of Infectious Diseases
Volume190
Issue number9
DOIs
StatePublished - Nov 1 2004

Fingerprint

Simian Immunodeficiency Virus
Lentivirus
Medroxyprogesterone Acetate
Macaca mulatta
Primates
Macaca
Vaccines
HIV
Attenuated Vaccines
Viral RNA
Infection
Progesterone
Acquired Immunodeficiency Syndrome
Viruses
Safety

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of Depo-Provera before intravaginal challenge with simian immunodeficiency virus mac239. / Abel, Kristina; Rourke, Tracy; Lu, Ding; Bost, Kristen; McChesney, Michael B.; Miller, Chris J.

In: Journal of Infectious Diseases, Vol. 190, No. 9, 01.11.2004, p. 1697-1705.

Research output: Contribution to journalArticle

@article{b82d2ceae8904c6ca3dc80f112a3813f,
title = "Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of Depo-Provera before intravaginal challenge with simian immunodeficiency virus mac239",
abstract = "In nonhuman primate models of acquired immunodeficiency syndrome, live attenuated lentiviruses provide the most reliable protection from systemic and mucosal challenge with pathogenic simian immunodeficiency virus (SIV). Although live attenuated lentiviruses may never be used in humans because of safety concerns, understanding the nature of the protective immune mechanisms induced by live attenuated vaccines in primate models will be useful for developing other vaccine approaches. Approximately 60{\%} of rhesus macaques immunized with nonpathogenic simian-human immunodeficiency virus (SHIV) strain 89.6 are protected from infection or clinical disease after intravaginal (IVAG) challenge with pathogenic SIVmac239. The goal of the present study was to determine whether administration of Depo-Provera before IVAG challenge with SIV decreases the protective efficacy of infection with SHIV89.6. The rate of protection after IVAG challenge with SIVmac239 was significantly lower (P < .05), and the acute postchallenge plasma viral RNA levels were significantly higher (P < .006), in Depo-Provera-treated, SHIV89.6-immunized macaques than in Depo-Proveranaive, SHIV89.6-immunized macaques. In the primate model of sexual transmission of human immunodeficiency virus, treatment with progesterone before IVAG challenge with a pathogenic virus can decrease the efficacy of a model {"}vaccine.{"}.",
author = "Kristina Abel and Tracy Rourke and Ding Lu and Kristen Bost and McChesney, {Michael B.} and Miller, {Chris J}",
year = "2004",
month = "11",
day = "1",
doi = "10.1086/424600",
language = "English (US)",
volume = "190",
pages = "1697--1705",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of Depo-Provera before intravaginal challenge with simian immunodeficiency virus mac239

AU - Abel, Kristina

AU - Rourke, Tracy

AU - Lu, Ding

AU - Bost, Kristen

AU - McChesney, Michael B.

AU - Miller, Chris J

PY - 2004/11/1

Y1 - 2004/11/1

N2 - In nonhuman primate models of acquired immunodeficiency syndrome, live attenuated lentiviruses provide the most reliable protection from systemic and mucosal challenge with pathogenic simian immunodeficiency virus (SIV). Although live attenuated lentiviruses may never be used in humans because of safety concerns, understanding the nature of the protective immune mechanisms induced by live attenuated vaccines in primate models will be useful for developing other vaccine approaches. Approximately 60% of rhesus macaques immunized with nonpathogenic simian-human immunodeficiency virus (SHIV) strain 89.6 are protected from infection or clinical disease after intravaginal (IVAG) challenge with pathogenic SIVmac239. The goal of the present study was to determine whether administration of Depo-Provera before IVAG challenge with SIV decreases the protective efficacy of infection with SHIV89.6. The rate of protection after IVAG challenge with SIVmac239 was significantly lower (P < .05), and the acute postchallenge plasma viral RNA levels were significantly higher (P < .006), in Depo-Provera-treated, SHIV89.6-immunized macaques than in Depo-Proveranaive, SHIV89.6-immunized macaques. In the primate model of sexual transmission of human immunodeficiency virus, treatment with progesterone before IVAG challenge with a pathogenic virus can decrease the efficacy of a model "vaccine.".

AB - In nonhuman primate models of acquired immunodeficiency syndrome, live attenuated lentiviruses provide the most reliable protection from systemic and mucosal challenge with pathogenic simian immunodeficiency virus (SIV). Although live attenuated lentiviruses may never be used in humans because of safety concerns, understanding the nature of the protective immune mechanisms induced by live attenuated vaccines in primate models will be useful for developing other vaccine approaches. Approximately 60% of rhesus macaques immunized with nonpathogenic simian-human immunodeficiency virus (SHIV) strain 89.6 are protected from infection or clinical disease after intravaginal (IVAG) challenge with pathogenic SIVmac239. The goal of the present study was to determine whether administration of Depo-Provera before IVAG challenge with SIV decreases the protective efficacy of infection with SHIV89.6. The rate of protection after IVAG challenge with SIVmac239 was significantly lower (P < .05), and the acute postchallenge plasma viral RNA levels were significantly higher (P < .006), in Depo-Provera-treated, SHIV89.6-immunized macaques than in Depo-Proveranaive, SHIV89.6-immunized macaques. In the primate model of sexual transmission of human immunodeficiency virus, treatment with progesterone before IVAG challenge with a pathogenic virus can decrease the efficacy of a model "vaccine.".

UR - http://www.scopus.com/inward/record.url?scp=6944244828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6944244828&partnerID=8YFLogxK

U2 - 10.1086/424600

DO - 10.1086/424600

M3 - Article

VL - 190

SP - 1697

EP - 1705

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 9

ER -